BioMarin Pharmaceutical (NASDAQ: BMRN) has been a rough investment for a long time. Over the past 10 years, shares have provided a total return of -28%. However, Wall Street analysts have consistently given this stock price targets that are much higher than its trading price.
They see more fundamental value in the company than the market will give it credit for. That remains true today. The stock’s average price target of $94 implies that shares would need to rise 53% to meet that level. So, can BioMarin Pharma reach the potential analysts have placed on it, or is avoiding this stock a better idea?
